 |
|
|
|
 |
A Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy-naïve Patients with Advanced/Metastatic Urothelial Carcinoma
[Protocol 06-006]
- Full Title :
- PHASE II TRIAL OF GEMCITABINE, CARBOPLATIN, AND BEVACIZUMAB IN CHEMOTHERAPY NAIVE PATIENTS WITH ADVANCED/METASTATIC UROTHELIAL CARCINOMA
- Purpose :
Gemcitabine and carboplatin are two standard chemotherapy drugs used to treat tumors of the urothelial tract. These drugs do not shrink tumors in all patients, however, and when they do, it is generally for a limited amount of time. Scientists are therefore seeking more effective ways to treat these cancers.
The purpose of this study is to evaluate the effectiveness of adding another anticancer drug, bevacizumab, to the combination of gemcitabine and carboplatin in patients with advanced urothelial cancers. Bevacizumab is used to treat advanced colon cancer, under the name Avastin®. It may prevent the development of the blood vessels that tumors need to grow and spread.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis that cannot be surgically removed or has metastasized.
- Patients may not be eligible or able to receive cisplatin.
- Patients may not have had prior chemotherapy.
- At least 4 weeks must have passed since prior radiation therapy or major surgery and entry into the study.
- Patients must be age 18 or older.
For more information and to see if you are eligible for this study, please contact Dr. Dana E. Rathkopf at 646-422-4379.
|
|
|
|
|
